Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology ...

Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of ...

In recent trading, shares of Ionis Pharmaceuticals Inc (NASD: IONS) have crossed above the average analyst 12-month target price of $29.29, changing hands for $38.01/share.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $59.00. Yaron Werber’s rating is based ...

Ionis Pharmaceuticals IONS has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ionis Pharmaceuticals IONS has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 5,610 call options on the company. This is an increase ...

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a ...

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.